Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the sale, the insider now owns 6,981 shares of the company’s stock, valued at approximately $33,508.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Barry Ticho also recently made the following trade(s):
- On Tuesday, January 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $5.74, for a total value of $57,400.00.
Stoke Therapeutics Trading Up 5.6 %
Shares of STOK stock opened at $4.71 on Wednesday. The stock has a market cap of $210.30 million, a P/E ratio of -1.95 and a beta of 0.52. The stock has a 50 day simple moving average of $4.94 and a 200 day simple moving average of $4.84. Stoke Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $14.00.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in Stoke Therapeutics by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after purchasing an additional 837 shares in the last quarter. American International Group Inc. raised its position in Stoke Therapeutics by 10.9% during the second quarter. American International Group Inc. now owns 10,506 shares of the company’s stock valued at $139,000 after purchasing an additional 1,029 shares in the last quarter. Great West Life Assurance Co. Can raised its position in Stoke Therapeutics by 46.7% during the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in Stoke Therapeutics during the first quarter valued at approximately $25,000. Finally, Point72 Hong Kong Ltd acquired a new position in Stoke Therapeutics during the first quarter valued at approximately $27,000.
Analyst Ratings Changes
Separately, Needham & Company LLC reduced their price objective on Stoke Therapeutics from $25.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, November 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
- Five stocks we like better than Stoke Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Is the dip in Atlassian stock a sneaky buy opportunity?
- How to Buy Cheap Stocks Step by Step
- Caterpillar stock hits new highs; time to ring the register?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.